Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Apr;23(4):727-38.
doi: 10.1681/ASN.2011070688. Epub 2012 Feb 23.

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder

Affiliations
Randomized Controlled Trial

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder

John T Daugirdas et al. J Am Soc Nephrol. 2012 Apr.

Abstract

More frequent hemodialysis sessions and longer session lengths may offer improved phosphorus control. We analyzed data from the Frequent Hemodialysis Network Daily and Nocturnal Trials to examine the effects of treatment assignment on predialysis serum phosphorus and on prescribed dose of phosphorus binder, expressed relative to calcium carbonate on a weight basis. In the Daily Trial, with prescribed session lengths of 1.5-2.75 hours six times per week, assignment to frequent hemodialysis associated with both a 0.46 mg/dl decrease (95% confidence interval [95% CI], 0.13-0.78 mg/dl) in mean serum phosphorus and a 1.35 g/d reduction (95% CI, 0.20-2.50 g/d) in equivalent phosphorus binder dose at month 12 compared with assignment to conventional hemodialysis. In the Nocturnal Trial, with prescribed session lengths of 6-8 hours six times per week, assignment to frequent hemodialysis associated with a 1.24 mg/dl decrease (95% CI, 0.68-1.79 mg/dl) in mean serum phosphorus compared with assignment to conventional hemodialysis. Among patients assigned to the group receiving six sessions per week, 73% did not require phosphorus binders at month 12 compared with only 8% of patients assigned to sessions three times per week (P<0.001). At month 12, 42% of patients on nocturnal hemodialysis required the addition of phosphorus into the dialysate to prevent hypophosphatemia. Frequent hemodialysis did not have major effects on calcium or parathyroid hormone concentrations in either trial. In conclusion, frequent hemodialysis facilitates control of hyperphosphatemia and extended session lengths could allow more liberal diets and freedom from phosphorus binders.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Adjusted mean levels of serum phosphorus. Monthly predialysis serum phosphorus in participants in the (A) Daily Trial and (B) Nocturnal Trial.
Figure 2.
Figure 2.
Predialysis phosphorus at the end of the study. Distribution of predialysis serum phosphorus among participants in the (A) Daily Trial and (B) Nocturnal Trial.
Figure 3.
Figure 3.
Number of different phosphorus binders taken at baseline and at the end of the study. Binders were grouped into six classes depending on whether they contained calcium carbonate, calcium acetate, sevelamer, lanthanum, aluminum, or magnesium plus calcium. (A) Participants in the Daily Trial. The top row depicts the control arm at baseline (left panel) and month 12 (right panel, and the bottom row depicts the six times per week arm at the same time points). (B) Participants in the Nocturnal Trial. The top row depicts the control arm at baseline (left panel) and month 12 (right panel, and the bottom row depicts the six times per week arm at the same time points).
Figure 4.
Figure 4.
Serum PTH levels at baseline and month 12 of follow-up. Distribution of PTH in participants in the (A) Daily Trial and (B) Nocturnal Trial.

Comment in

Similar articles

Cited by

References

    1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004 - PubMed
    1. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 333: 166–174, 1995 - PubMed
    1. Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K: Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88: 1511–1518, 2008 - PMC - PubMed
    1. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4: 1089–1096, 2009 - PMC - PubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1–S130, 2009 - PubMed

Publication types

MeSH terms